These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 4225560)

  • 21. Nursing management--cancer chemotherapy.
    Lane CG
    J Nurs Care; 1980 Oct; 13(10):7-11. PubMed ID: 6903601
    [No Abstract]   [Full Text] [Related]  

  • 22. Experience with ftorafur treatment in breast cancer.
    Karev NI; Blokhina NG; Vozny EK; Pershin MP
    Neoplasma; 1972; 19(4):347-50. PubMed ID: 5054534
    [No Abstract]   [Full Text] [Related]  

  • 23. Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
    Zalupski MM; Baker LH
    J Infus Chemother; 1995; 5(3):129-31. PubMed ID: 8528970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0].
    Kaba H; Fukuda H; Yamamoto S; Ohashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1187-92. PubMed ID: 15332541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical effects of prolonged intravenous infusion of 5-fluoro-2'-deoxyuridine.
    Sullivan RD; Miller E
    Cancer Res; 1965 Aug; 25(7):1025-33. PubMed ID: 4284747
    [No Abstract]   [Full Text] [Related]  

  • 26. [A clinical study of N-nitrosomethylurea].
    Vermel' EM; Korman NP; Milonov BV; Evseenko LS; Orlova RS
    Vopr Onkol; 1970 May; 16(5):31-7. PubMed ID: 4915916
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
    Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
    Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
    Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
    Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Carrato A; Antón-Torres A; Massutí T; Fernández-Martos C; Díaz-Rubio E
    J Infus Chemother; 1996; 6(3):118-22. PubMed ID: 9229321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of crossing-over between 30-minute drip infusion vs 30-second injection of granisetron for nausea and vomitting with cisplatin].
    Satoh Y; Oshima T; Takahashi N; Ogawa H; Shiroto H; Akasaka Y; Nakanishi Y; Uchino J; Koshino I; Une Y; Todo S
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2101-8. PubMed ID: 9838913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
    Windschitl H; Scott M; Schutt A; McCormack G; Everson L; Cullinan S; Gerstner J; Krook J; Laurie J; Shreck R
    Cancer Treat Rep; 1983 Nov; 67(11):1001-8. PubMed ID: 6640551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical evaluation of granisetron injection against nausea and vomiting induced by anticancer drugs including cisplatin].
    Yoshiya N; Kodama S; Tanaka K; Hataya I; Tokunaga A; Takeuchi Y; Hanaoka J; Yanase T; Takahashi T; Maruhashi T
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1641-6. PubMed ID: 8060140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
    Lokich J; Corkery J
    Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mucocutaneous side effects of Brequinar sodium. A new inhibitor of pyrimidine de novo biosynthesis.
    Schwartsmann G; Bork E; Vermorken JB; Nieboer C; Dodion P; ten Bokkel Huinink WW; Seldenrijk CA; Armand JP; Pinedo HM
    Cancer; 1989 Jan; 63(2):243-8. PubMed ID: 2521297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
    Noguchi S; Shuin T; Kubota Y; Masuda M; Yao M; Hosaka M
    Hinyokika Kiyo; 1995 Jul; 41(7):517-20. PubMed ID: 7668181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
    ANSFIELD FJ; CURRERI AR
    Cancer Chemother Rep; 1963 Oct; 32():101-5. PubMed ID: 14088828
    [No Abstract]   [Full Text] [Related]  

  • 38. [Toxicity and cumulative properties of actinomycins C1, C2 and C3, contained in preparations in various combinations].
    Lupinosov IuV; Denisova SI; Syrkin AB; Gogoleva IA
    Antibiotiki; 1971 May; 16(5):443-6. PubMed ID: 4108776
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose intermittent intravenous infusion of procarbazine (NSC-77213).
    Chabner BA; Sponzo R; Hubbard S; Canellos GP; Young RC; Schein PS; Devita VT
    Cancer Chemother Rep; 1973; 57(3):361-3. PubMed ID: 4584487
    [No Abstract]   [Full Text] [Related]  

  • 40. STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
    MCCAFFERY JF
    Med J Aust; 1964 Oct; 2():582-5. PubMed ID: 14220311
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.